The Pleiotropic Effects of the GM-CSF Rheostat on Myeloid Cell Differentiation and Function: More Than a Numbers Game
Yifan Zhan, Andrew M Lew, Michael Chopin, Yifan Zhan, Andrew M Lew, Michael Chopin
Abstract
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a myelopoietic growth factor that has pleiotropic effects not only in promoting the differentiation of immature precursors into polymorphonuclear neutrophils (PMNs), monocytes/macrophages (MØs) and dendritic cells (DCs), but also in controlling the function of fully mature myeloid cells. This broad spectrum of GM-CSF action may elicit paradoxical outcomes-both immunostimulation and immunosuppression-in infection, inflammation, and cancer. The complexity of GM-CSF action remains to be fully unraveled. Several aspects of GM-CSF action could contribute to its diverse biological consequences. Firstly, GM-CSF as a single cytokine affects development of most myeloid cells from progenitors to mature immune cells. Secondly, GM-CSF activates JAK2/STAT5 and also activate multiple signaling modules and transcriptional factors that direct different biological processes. Thirdly, GM-CSF can be produced by different cell types including tumor cells in response to different environmental cues; thus, GM-CSF quantity can vary greatly under different pathophysiological settings. Finally, GM-CSF signaling is also fine-tuned by other less defined feedback mechanisms. In this review, we will discuss the role of GM-CSF in orchestrating the differentiation, survival, and proliferation during the generation of multiple lineages of myeloid cells (PMNs, MØs, and DCs). We will also discuss the role of GM-CSF in regulating the function of DCs and the functional polarization of MØs. We highlight how the dose of GM-CSF and corresponding signal strength acts as a rheostat to fine-tune cell fate, and thus the way GM-CSF may best be targeted for immuno-intervention in infection, inflammation and cancer.
Keywords: GM-CSF; dendritic cells; differentiation; function; macrophages.
Copyright © 2019 Zhan, Lew and Chopin.
Figures
References
- Metcalf D. The molecular biology and functions of the granulocyte-macrophage colony-stimulating factors. Blood. (1986) 67:257–67. 10.1182/blood.V67.2.257.257
- Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, et al. . Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med. (1992) 176:1693–702. 10.1084/jem.176.6.1693
- Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, et al. . An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. (1999) 223:77–92. 10.1016/S0022-1759(98)00204-X
- Helft J, Bottcher J, Chakravarty P, Zelenay S, Huotari J, Schraml BU, et al. . GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity. (2015) 42:1197–211. 10.1016/j.immuni.2015.05.018
- Sun L, Rautela J, Delconte RB, Souza-Fonseca-Guimaraes F, Carrington EM, Schenk RL, et al. . GM-CSF quantity has a selective effect on granulocytic vs. monocytic myeloid development and function. Front Immunol. (2018) 9:1922. 10.3389/fimmu.2018.01922
- Jin D, Sprent J. GM-CSF culture revisited: preparation of bulk populations of highly pure dendritic cells from mouse bone marrow. J Immunol. (2018) 201:3129–39. 10.4049/jimmunol.1800031
- Dranoff G, Crawford AD, Sadelain M, Ream B, Rashid A, Bronson RT, et al. . Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. (1994) 264:713–6. 10.1126/science.8171324
- Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. . Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA. (1994) 91:5592–6. 10.1073/pnas.91.12.5592
- Greter M, Helft J, Chow A, Hashimoto D, Mortha A, Agudo-Cantero J, et al. . GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity. (2012) 36:1031–46. 10.1016/j.immuni.2012.03.027
- Schneider C, Nobs SP, Kurrer M, Rehrauer H, Thiele C, Kopf M. Induction of the nuclear receptor PPAR-gamma by the cytokine GM-CSF is critical for the differentiation of fetal monocytes into alveolar macrophages. Nat Immunol. (2014) 15:1026–37. 10.1038/ni.3005
- Lang RA, Metcalf D, Cuthbertson RA, Lyons I, Stanley E, Kelso A, et al. . Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell. (1987) 51:675–86. 10.1016/0092-8674(87)90136-X
- van Nieuwenhuijze AE, Coghill E, Gray D, Prato S, Metcalf D, Alexander WS, et al. . Transgenic expression of GM-CSF in T cells causes disseminated histiocytosis. Am J Pathol. (2014) 184:184–99. 10.1016/j.ajpath.2013.09.014
- Jinushi M, Hodi FS, Dranoff G. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev. (2008) 222:287–98. 10.1111/j.1600-065X.2008.00618.x
- Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. (2008) 8:533–44. 10.1038/nri2356
- Becher B, Tugues S, Greter M. GM-CSF: from growth factor to central mediator of tissue inflammation. Immunity. (2016) 45:963–73. 10.1016/j.immuni.2016.10.026
- Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol. (2016) 12:37–48. 10.1038/nrrheum.2015.161
- Dougan M, Dranoff G, Dougan SK. GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation. Immunity. (2019) 50:796–811. 10.1016/j.immuni.2019.03.022
- van de Laar L, Coffer PJ, Woltman AM. Regulation of dendritic cell development by GM-CSF: molecular control and implications for immune homeostasis and therapy. Blood. (2012) 119:3383–93. 10.1182/blood-2011-11-370130
- Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, et al. . Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J. (2006) 25:479–89. 10.1038/sj.emboj.7600948
- Hercus TR, Thomas D, Guthridge MA, Ekert PG, King-Scott J, Parker MW, et al. . The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood. (2009) 114:1289–98. 10.1182/blood-2008-12-164004
- Gribben JG, Devereux S, Thomas NS, Keim M, Jones HM, Goldstone AH, et al. . Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet. (1990) 335:434–7. 10.1016/0140-6736(90)90665-R
- Kim J, Park H, Park BT, Hwang HS, Kim JI, Kim DK, et al. . O-glycans and O-glycosylation sites of recombinant human GM-CSF derived from suspension-cultured rice cells, and their structural role. Biochem Biophys Res Commun. (2016) 479:266–71. 10.1016/j.bbrc.2016.09.057
- Ding DX, Vera JC, Heaney ML, Golde DW. N-glycosylation of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit is essential for ligand binding and signal transduction. J Biol Chem. (1995) 270:24580–4. 10.1074/jbc.270.41.24580
- Niu L, Heaney ML, Vera JC, Golde DW. High-affinity binding to the GM-CSF receptor requires intact N-glycosylation sites in the extracellular domain of the beta subunit. Blood. (2000) 95:3357–62. 10.1182/blood.V95.11.3357
- Arranz A, Doxaki C, Vergadi E, Martinez de la Torre Y, Vaporidi K, Lagoudaki ED, et al. . Akt1 and Akt2 protein kinases differentially contribute to macrophage polarization. Proc Natl Acad Sci USA. (2012) 109:9517–22. 10.1073/pnas.1119038109
- Burgess AW, Camakaris J, Metcalf D. Purification and properties of colony-stimulating factor from mouse lung-conditioned medium. J Biol Chem. (1977) 252:1998–2003.
- Kelso A, Owens T. Production of two hemopoietic growth factors is differentially regulated in single T lymphocytes activated with an anti-T cell receptor antibody. J Immunol. (1988) 140:1159–67.
- Campbell IK, van Nieuwenhuijze A, Segura E, O'Donnell K, Coghill E, Hommel M, et al. . Differentiation of inflammatory dendritic cells is mediated by NF-κB1-dependent GM-CSF production in CD4 T cells. J Immunol. (2011) 186:5468–77. 10.4049/jimmunol.1002923
- Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. . RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. (2011) 12:560–7. 10.1038/ni.2027
- El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, et al. . The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. (2011) 12:568–75. 10.1038/ni.2031
- Zhang AL, Colmenero P, Purath U, Teixeira de Matos C, Hueber W, Klareskog L, et al. . Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood. (2007) 110:2484–93. 10.1182/blood-2007-02-076364
- Wodnar-Filipowicz A, Heusser CH, Moroni C. Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature. (1989) 339:150–2. 10.1038/339150a0
- Lenhoff S, Sallerfors B, Olofsson T. IL-10 as an autocrine regulator of CSF secretion by monocytes: disparate effects on GM-CSF and G-CSF secretion. Exp Hematol. (1998) 26:299–304.
- Broudy VC, Kaushansky K, Harlan JM, Adamson JW. Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol. (1987) 139:464–8.
- Zucali JR, Dinarello CA, Oblon DJ, Gross MA, Anderson L, Weiner RS. Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest. (1986) 77:1857–63. 10.1172/JCI112512
- Guilliams M, De Kleer I, Henri S, Post S, Vanhoutte L, De Prijck S, et al. . Alveolar macrophages develop from fetal monocytes that differentiate into long-lived cells in the first week of life via GM-CSF. J Exp Med. (2013) 210:1977–92. 10.1084/jem.20131199
- Pierson ER, Goverman JM. GM-CSF is not essential for experimental autoimmune encephalomyelitis but promotes brain-targeted disease. JCI Insight. (2017) 2:e92362 10.1172/jci.insight.92362
- Rothchild AC, Stowell B, Goyal G, Nunes-Alves C, Yang Q, Papavinasasundaram K, et al. . Role of granulocyte-macrophage colony-stimulating factor production by T cells during Mycobacterium tuberculosis infection. MBio. (2017) 8:e01514-17. 10.1128/mBio.01514-17
- Xu Y, Zhan Y, Lew AM, Naik SH, Kershaw MH. Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking. J Immunol. (2007) 179:7577–84. 10.4049/jimmunol.179.11.7577
- Demirci U, Coskun U, Sancak B, Ozturk B, Bahar B, Benekli M, et al. . Serum granulocyte macrophage-colony stimulating factor: a tumor marker in colorectal carcinoma? Asian Pac J Cancer Prev. (2009) 10:1021–4.
- Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ. Cytokines in chronic inflammatory arthritis. II Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest. (1989) 83:876–82. 10.1172/JCI113971
- Fiehn C, Wermann M, Pezzutto A, Hufner M, Heilig B. [Plasma GM-CSF concentrations in rheumatoid arthritis, systemic lupus erythematosus and spondyloarthropathy]. Z Rheumatol. (1992) 51:121–6.
- Noguchi M, Hiwatashi N, Liu ZX, Toyota T. Increased secretion of granulocyte-macrophage colony-stimulating factor in mucosal lesions of inflammatory bowel disease. Digestion. (2001) 63(Suppl. 1):32–6. 10.1159/000051908
- Benmerzoug S, Marinho FV, Rose S, Mackowiak C, Gosset D, Sedda D, et al. . GM-CSF targeted immunomodulation affects host response to M. tuberculosis infection. Sci Rep. (2018) 8:8652. 10.1038/s41598-018-26984-3
- Cheers C, Haigh AM, Kelso A, Metcalf D, Stanley ER, Young AM. Production of colony-stimulating factors (CSFs) during infection: separate determinations of macrophage-, granulocyte-, granulocyte-macrophage-, and multi-CSFs. Infect Immun. (1988) 56:247–51.
- Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, et al. . Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. (1988) 318:869–76. 10.1056/NEJM198804073181401
- Bronte V, Chappell DB, Apolloni E, Cabrelle A, Wang M, Hwu P, et al. . Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol. (1999) 162:5728–37.
- Zarei S, Schwenter F, Luy P, Aurrand-Lions M, Morel P, Kopf M, et al. . Role of GM-CSF signaling in cell-based tumor immunization. Blood. (2009) 113:6658–68. 10.1182/blood-2008-06-161075
- Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ, et al. . Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. (2012) 21:822–35. 10.1016/j.ccr.2012.04.025
- Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. (1993) 90:3539–43. 10.1073/pnas.90.8.3539
- Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, et al. . Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci USA. (1998) 95:13141–6. 10.1073/pnas.95.22.13141
- Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, et al. . Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. (1999) 59:5160–8.
- Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K, et al. . Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol. (2003) 21:624–30. 10.1200/JCO.2003.03.091
- Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. (2007) 18:226–32. 10.1093/annonc/mdl158
- Kast RE, Hill QA, Wion D, Mellstedt H, Focosi D, Karpel-Massler G, et al. . Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumour Biol. (2017) 39:1010428317699797. 10.1177/1010428317699797
- Hazenberg BP, Van Leeuwen MA, Van Rijswijk MH, Stern AC, Vellenga E. Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colony-stimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood. (1989) 74:2769–70. 10.1182/blood.V74.8.2769.2769
- de Vries EG, Willemse PH, Biesma B, Stern AC, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet. (1991) 338:517–8. 10.1016/0140-6736(91)90594-F
- Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol Immunotoxicol. (1998) 20:373–82. 10.3109/08923979809034820
- Campbell IK, Rich MJ, Bischof RJ, Dunn AR, Grail D, Hamilton JA. Protection from collagen-induced arthritis in granulocyte-macrophage colony-stimulating factor-deficient mice. J Immunol. (1998) 161:3639–44.
- McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, et al. . Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. (2001) 194:873–82. 10.1084/jem.194.7.873
- Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. (2001) 3:293–8. 10.1186/ar318
- Cook AD, Turner AL, Braine EL, Pobjoy J, Lenzo JC, Hamilton JA. Regulation of systemic and local myeloid cell subpopulations by bone marrow cell-derived granulocyte-macrophage colony-stimulating factor in experimental inflammatory arthritis. Arthritis Rheum. (2011) 63:2340–51. 10.1002/art.30354
- Huizinga TW, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, et al. . Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis. Arthritis Res Ther. (2017) 19:53. 10.1186/s13075-017-1267-3
- Behrens F, Tak PP, Ostergaard M, Stoilov R, Wiland P, Huizinga TW, et al. . MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis. (2015) 74:1058–64. 10.1136/annrheumdis-2013-204816
- Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Godwood A, et al. . Mavrilimumab, a fully human granulocyte-macrophage colony-stimulating factor receptor alpha monoclonal antibody: long-term safety and efficacy in patients with rheumatoid arthritis. Arthritis Rheumatol. (2018) 70:679–89. 10.1002/art.40420
- Weinblatt ME, McInnes IB, Kremer JM, Miranda P, Vencovsky J, Guo X, et al. . A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis. Arthritis Rheumatol. (2018) 70:49–59. 10.1002/art.40323
- Bhattacharya P, Thiruppathi M, Elshabrawy HA, Alharshawi K, Kumar P, Prabhakar BS. GM-CSF: an immune modulatory cytokine that can suppress autoimmunity. Cytokine. (2015) 75:261–71. 10.1016/j.cyto.2015.05.030
- Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group . Sargramostim for active Crohn's disease. N Engl J Med. (2005) 352:2193–201. 10.1056/NEJMoa041109
- Gaudreau S, Guindi C, Menard M, Besin G, Dupuis G, Amrani A. Granulocyte-macrophage colony-stimulating factor prevents diabetes development in NOD mice by inducing tolerogenic dendritic cells that sustain the suppressive function of CD4+CD25+ regulatory T cells. J Immunol. (2007) 179:3638–47. 10.4049/jimmunol.179.6.3638
- Enzler T, Gillessen S, Manis JP, Ferguson D, Fleming J, Alt FW, et al. . Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med. (2003) 197:1213–9. 10.1084/jem.20021258
- Enzler T, Gillessen S, Dougan M, Allison JP, Neuberg D, Oble DA, et al. . Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulitis and destruction of beta cells. Blood. (2007) 110:954–61. 10.1182/blood-2006-08-043786
- Vasu C, Dogan RN, Holterman MJ, Prabhakar BS. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol. (2003) 170:5511–22. 10.4049/jimmunol.170.11.5511
- Moorman CD, Curtis AD, II, Bastian AG, Elliott SE, Mannie MD. A GMCSF-neuroantigen tolerogenic vaccine elicits systemic lymphocytosis of CD4(+) CD25(high) FOXP3(+) regulatory T cells in myelin-specific TCR transgenic mice contingent upon low-efficiency T cell antigen receptor recognition. Front Immunol. (2018) 9:3119 10.3389/fimmu.2018.03119
- Kared H, Leforban B, Montandon R, Renand A, Layseca Espinosa E, Chatenoud L, et al. . Role of GM-CSF in tolerance induction by mobilized hematopoietic progenitors. Blood. (2008) 112:2575–8. 10.1182/blood-2008-02-140681
- Ribechini E, Hutchinson JA, Hergovits S, Heuer M, Lucas J, Schleicher U, et al. . Novel GM-CSF signals via IFN-gammaR/IRF-1 and AKT/mTOR license monocytes for suppressor function. Blood Adv. (2017) 1:947–60. 10.1182/bloodadvances.2017006858
- Salehi S, Reed EF. The divergent roles of macrophages in solid organ transplantation. Curr Opin Organ Transplant. (2015) 20:446–53. 10.1097/MOT.0000000000000209
- Tugues S, Amorim A, Spath S, Martin-Blondel G, Schreiner B, De Feo D, et al. Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. Sci Transl Med. (2018) 10:eaat8410 10.1126/scitranslmed.aat8410
- Nishinakamura R, Miyajima A, Mee PJ, Tybulewicz VL, Murray R. Hematopoiesis in mice lacking the entire granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood. (1996) 88:2458–64. 10.1182/blood.V88.7.2458.bloodjournal8872458
- Zhan Y, Lieschke GJ, Grail D, Dunn AR, Cheers C. Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood. (1998) 91:863–9. 10.1182/blood.V91.3.863
- Gonzalez-Juarrero M, Hattle JM, Izzo A, Junqueira-Kipnis AP, Shim TS, Trapnell BC, et al. . Disruption of granulocyte macrophage-colony stimulating factor production in the lungs severely affects the ability of mice to control Mycobacterium tuberculosis infection. J Leukoc Biol. (2005) 77:914–22. 10.1189/jlb.1204723
- Morrissey PJ, Charrier K. GM-CSF administration augments the survival of ity-resistant A/J mice, but not ity-susceptible C57BL/6 mice, to a lethal challenge with Salmonella typhimurium. J Immunol. (1990) 144:557–61.
- Nambiar JK, Ryan AA, Kong CU, Britton WJ, Triccas JA. Modulation of pulmonary DC function by vaccine-encoded GM-CSF enhances protective immunity against Mycobacterium tuberculosis infection. Eur J Immunol. (2010) 40:153–61. 10.1002/eji.200939665
- Riopel J, Tam M, Mohan K, Marino MW, Stevenson MM. Granulocyte-macrophage colony-stimulating factor-deficient mice have impaired resistance to blood-stage malaria. Infect Immun. (2001) 69:129–36. 10.1128/IAI.69.1.129-136.2001
- Olivares Fontt E, Heirman C, Thielemans K, Vray B. Granulocyte-macrophage colony-stimulating factor: involvement in control of Trypanosoma cruzi infection in mice. Infect Immun. (1996) 64:3429–34.
- Murray HW, Cervia JS, Hariprashad J, Taylor AP, Stoeckle MY, Hockman H. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J Clin Invest. (1995) 95:1183–92. 10.1172/JCI117767
- Grau GE, Kindler V, Piguet PF, Lambert PH, Vassalli P. Prevention of experimental cerebral malaria by anticytokine antibodies. Interleukin 3 and granulocyte macrophage colony-stimulating factor are intermediates in increased tumor necrosis factor production and macrophage accumulation. J Exp Med. (1988) 168:1499–504. 10.1084/jem.168.4.1499
- du Plessis N, Loebenberg L, Kriel M, von Groote-Bidlingmaier F, Ribechini E, Loxton AG, et al. . Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med. (2013) 188:724–32. 10.1164/rccm.201302-0249OC
- Mencacci A, Montagnoli C, Bacci A, Cenci E, Pitzurra L, Spreca A, et al. . CD80+Gr-1+ myeloid cells inhibit development of antifungal Th1 immunity in mice with candidiasis. J Immunol. (2002) 169:3180–90. 10.4049/jimmunol.169.6.3180
- Sponaas AM, Freitas do Rosario AP, Voisine C, Mastelic B, Thompson J, Koernig S, et al. . Migrating monocytes recruited to the spleen play an important role in control of blood stage malaria. Blood. (2009) 114:5522–31. 10.1182/blood-2009-04-217489
- Goni O, Alcaide P, Fresno M. Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+)immature myeloid suppressor cells. Int Immunol. (2002) 14:1125–34. 10.1093/intimm/dxf076
- Bowen JL, Olson JK. Innate immune CD11b+Gr-1+ cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease. J Immunol. (2009) 183:6971–80. 10.4049/jimmunol.0902193
- Metcalf D. Clonal analysis of proliferation and differentiation of paired daughter cells: action of granulocyte-macrophage colony-stimulating factor on granulocyte-macrophage precursors. Proc Natl Acad Sci USA. (1980) 77:5327–30. 10.1073/pnas.77.9.5327
- Weston BR, Li L, Tyson JJ. Mathematical analysis of cytokine-induced differentiation of granulocyte-monocyte progenitor cells. Front Immunol. (2018) 9:2048. 10.3389/fimmu.2018.02048
- Brach MA, deVos S, Gruss HJ, Herrmann F. Prolongation of survival of human polymorphonuclear neutrophils by granulocyte-macrophage colony-stimulating factor is caused by inhibition of programmed cell death. Blood. (1992) 80:2920–4. 10.1182/blood.V80.11.2920.2920
- Smith WB, Guida L, Sun Q, Korpelainen EI, van den Heuvel C, Gillis D, et al. . Neutrophils activated by granulocyte-macrophage colony-stimulating factor express receptors for interleukin-3 which mediate class II expression. Blood. (1995) 86:3938–44. 10.1182/blood.V86.10.3938.bloodjournal86103938
- Guthridge MA, Barry EF, Felquer FA, McClure BJ, Stomski FC, Ramshaw H, et al. . The phosphoserine-585-dependent pathway of the GM-CSF/IL-3/IL-5 receptors mediates hematopoietic cell survival through activation of NF-kappaB and induction of bcl-2. Blood. (2004) 103:820–7. 10.1182/blood-2003-06-1999
- Carrington EM, Tarlinton DM, Gray DH, Huntington ND, Zhan Y, Lew AM. The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules. Immunol Cell Biol. (2017) 95:870–7. 10.1038/icb.2017.72
- Cowburn AS, Summers C, Dunmore BJ, Farahi N, Hayhoe RP, Print CG, et al. . Granulocyte/macrophage colony-stimulating factor causes a paradoxical increase in the BH3-only pro-apoptotic protein Bim in human neutrophils. Am J Respir Cell Mol Biol. (2011) 44:879–87. 10.1165/rcmb.2010-0101OC
- Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. . BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA. (2010) 107:10967–71. 10.1073/pnas.1005256107
- Leverson JD, Phillips DC, Mitten MJ, Boghaert ER, Diaz D, Tahir SK, et al. . Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med. (2015) 7:279ra40. 10.1126/scitranslmed.aaa4642
- Lin EY, Orlofsky A, Berger MS, Prystowsky MB. Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol. (1993) 151:1979–88.
- Vier J, Groth M, Sochalska M, Kirschnek S. The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling. Cell Death Dis. (2016) 7:e2103. 10.1038/cddis.2016.23
- Schenk RL, Tuzlak S, Carrington EM, Zhan Y, Heinzel S, Teh CE, et al. . Characterisation of mice lacking all functional isoforms of the pro-survival BCL-2 family member A1 reveals minor defects in the haematopoietic compartment. Cell Death Differ. (2017) 24:534–45. 10.1038/cdd.2016.156
- Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem. (2004) 279:26915–21. 10.1074/jbc.M313875200
- Andina N, Conus S, Schneider EM, Fey MF, Simon HU. Induction of Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death Differ. (2009) 16:1248–55. 10.1038/cdd.2009.50
- Dzhagalov I, St John A, He YW. The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood. (2007) 109:1620–6. 10.1182/blood-2006-03-013771
- Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. (1994) 179:1109–18. 10.1084/jem.179.4.1109
- Erlich Z, Shlomovitz I, Edry-Botzer L, Cohen H, Frank D, Wang H, et al. . Macrophages, rather than DCs, are responsible for inflammasome activity in the GM-CSF BMDC model. Nat Immunol. (2019) 20:397–406. 10.1038/s41590-019-0313-5
- Menezes S, Melandri D, Anselmi G, Perchet T, Loschko J, Dubrot J, et al. The heterogeneity of Ly6C(hi) monocytes controls their differentiation into iNOS(+) macrophages or monocyte-derived dendritic cells. Immunity. (2016) 45:1205–18. 10.1016/j.immuni.2016.12.001
- Lutz MB, Suri RM, Niimi M, Ogilvie AL, Kukutsch NA, Rossner S, et al. . Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol. (2000) 30, 1813–22. 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>;2-8
- Na YR, Jung D, Gu GJ, Seok SH. GM-CSF grown bone marrow derived cells are composed of phenotypically different dendritic cells and macrophages. Mol Cells. (2016) 39:734–41. 10.14348/molcells.2016.0160
- Bunda S, Kommaraju K, Heir P, Ohh M. SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor. PLoS ONE. (2013) 8:e76370. 10.1371/journal.pone.0076370
- Feldman GM, Rosenthal LA, Liu X, Hayes MP, Wynshaw-Boris A, Leonard WJ, et al. . STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood. (1997) 90:1768–76. 10.1182/blood.V90.5.1768
- Lehtonen A, Matikainen S, Miettinen M, Julkunen I. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced STAT5 activation and target-gene expression during human monocyte/macrophage differentiation. J Leukoc Biol. (2002) 71:511–9. 10.1189/jlb.71.3.511
- Miah MA, Yoon CH, Kim J, Jang J, Seong YR, Bae YS. CISH is induced during DC development and regulates DC-mediated CTL activation. Eur J Immunol. (2012) 42:58–68. 10.1002/eji.201141846
- Vento-Tormo R, Company C, Rodriguez-Ubreva J, de la Rica L, Urquiza JM, Javierre BM, et al. . IL-4 orchestrates STAT6-mediated DNA demethylation leading to dendritic cell differentiation. Genome Biol. (2016) 17:4. 10.1186/s13059-015-0863-2
- Pesu M, Aittomaki S, Valineva T, Silvennoinen O. PU.1 is required for transcriptional activation of the Stat6 response element in the Igepsilon promoter. Eur J Immunol. (2003) 33:1727–35. 10.1002/eji.200323680
- Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. . Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol. (2011) 12:247–54. 10.1038/ni.1995
- Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, et al. . Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol. (2002) 169:3574–80. 10.4049/jimmunol.169.7.3574
- Briseno CG, Haldar M, Kretzer NM, Wu X, Theisen DJ, Kc W, et al. . Distinct transcriptional programs control cross-priming in classical and monocyte-derived dendritic cells. Cell Rep. (2016) 15:2462–74. 10.1016/j.celrep.2016.05.025
- Piemonti L, Bernasconi S, Luini W, Trobonjaca Z, Minty A, Allavena P, et al. . IL-13 supports differentiation of dendritic cells from circulating precursors in concert with GM-CSF. Eur Cytokine Netw. (1995) 6:245–52.
- Ahn JS, Agrawal B. IL-4 is more effective than IL-13 for in vitro differentiation of dendritic cells from peripheral blood mononuclear cells. Int Immunol. (2005) 17:1337–46. 10.1093/intimm/dxh312
- Ko HJ, Brady JL, Ryg-Cornejo V, Hansen DS, Vremec D, Shortman K, et al. . GM-CSF-responsive monocyte-derived dendritic cells are pivotal in Th17 pathogenesis. J Immunol. (2014) 192:2202–9. 10.4049/jimmunol.1302040
- Croxford AL, Lanzinger M, Hartmann FJ, Schreiner B, Mair F, Pelczar P, et al. . The cytokine GM-CSF drives the inflammatory signature of CCR2+ monocytes and licenses autoimmunity. Immunity. (2015) 43:502–14. 10.1016/j.immuni.2015.08.010
- Chow KV, Lew AM, Sutherland RM, Zhan Y. Monocyte-derived dendritic cells promote Th polarization, whereas conventional dendritic cells promote th proliferation. J Immunol. (2016) 196:624–36. 10.4049/jimmunol.1501202
- Duncker PC, Stoolman JS, Huber AK, Segal BM. GM-CSF promotes chronic disability in experimental autoimmune encephalomyelitis by altering the composition of central nervous system-infiltrating cells, but is dispensable for disease induction. J Immunol. (2018) 200:966–73. 10.4049/jimmunol.1701484
- Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol. (2002) 2:151–61. 10.1038/nri746
- Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol. (2013) 31:563–604. 10.1146/annurev-immunol-020711-074950
- Mildner A, Jung S. Development and function of dendritic cell subsets. Immunity. (2014) 40:642–56. 10.1016/j.immuni.2014.04.016
- Guilliams M, Ginhoux F, Jakubzick C, Naik SH, Onai N, Schraml BU, et al. . Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. (2014) 14:571–8. 10.1038/nri3712
- Sathe P, Pooley J, Vremec D, Mintern J, Jin JO, Wu L, et al. . The acquisition of antigen cross-presentation function by newly formed dendritic cells. J Immunol. (2011) 186:5184–92. 10.4049/jimmunol.1002683
- Kingston D, Schmid MA, Onai N, Obata-Onai A, Baumjohann D, Manz MG. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood. (2009) 114:835–43. 10.1182/blood-2009-02-206318
- Zhan Y, Vega-Ramos J, Carrington EM, Villadangos JA, Lew AM, Xu Y. The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol. (2012) 42:2889–900. 10.1002/eji.201242477
- Esashi E, Wang YH, Perng O, Qin XF, Liu YJ, Watowich SS. The signal transducer STAT5 inhibits plasmacytoid dendritic cell development by suppressing transcription factor IRF8. Immunity. (2008) 28:509–20. 10.1016/j.immuni.2008.02.013
- Jiao Z, Bedoui S, Brady JL, Walter A, Chopin M, Carrington EM, et al. . The closely related CD103+ dendritic cells (DCs) and lymphoid-resident CD8+ DCs differ in their inflammatory functions. PLoS ONE. (2014) 9:e91126. 10.1371/journal.pone.0091126
- Zhan Y, Carrington EM, van Nieuwenhuijze A, Bedoui S, Seah S, Xu Y, et al. . GM-CSF increases cross-presentation and CD103 expression by mouse CD8 spleen dendritic cells. Eur J Immunol. (2011) 41:2585–95. 10.1002/eji.201141540
- Verreck FA, de Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, et al. . Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proc Natl Acad Sci USA. (2004) 101:4560–5. 10.1073/pnas.0400983101
- Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD. Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol. (2007) 178:5245–52. 10.4049/jimmunol.178.8.5245
- Fleetwood AJ, Dinh H, Cook AD, Hertzog PJ, Hamilton JA. GM-CSF- and M-CSF-dependent macrophage phenotypes display differential dependence on type I interferon signaling. J Leukoc Biol. (2009) 86:411–21. 10.1189/jlb.1108702
- Doherty TM, Coffman RL. Ability of macrophage subsets to transfer resistance to murine leishmaniasis is dependent on IL-12 production. Eur J Immunol. (1999) 29:522–9. 10.1002/(SICI)1521-4141(199902)29:02<522::AID-IMMU522>;2-U
- Morrissey PJ, Bressler L, Park LS, Alpert A, Gillis S. Granulocyte-macrophage colony-stimulating factor augments the primary antibody response by enhancing the function of antigen-presenting cells. J Immunol. (1987) 139:1113–9.
- Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, et al. . Granulocyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. (2000) 60:1934–41.
- Campo I. The influence of genetics on therapeutic developments in pulmonary alveolar proteinosis. Curr Opin Pulm Med. (2019) 25:294–9. 10.1097/MCP.0000000000000576
- Shibata Y, Berclaz PY, Chroneos ZC, Yoshida M, Whitsett JA, Trapnell BC. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity. (2001) 15:557–67. 10.1016/S1074-7613(01)00218-7
- Reed JA, Ikegami M, Cianciolo ER, Lu W, Cho PS, Hull W, et al. . Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol. (1999) 276:L556–63. 10.1152/ajplung.1999.276.4.L556
- Ohashi K, Sato A, Takada T, Arai T, Nei T, Kasahara Y, et al. . Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis. Respir Med. (2012) 106:284–93. 10.1016/j.rmed.2011.10.019
- Tran HT, Metcalf D, Cheers C. Anti-bacterial activity of peritoneal cells from transgenic mice producing high levels of GM-CSF. Immunology. (1990) 71:377–82.
- Sorgi CA, Rose S, Court N, Carlos D, Paula-Silva FW, Assis PA, et al. . GM-CSF priming drives bone marrow-derived macrophages to a pro-inflammatory pattern and downmodulates PGE2 in response to TLR2 ligands. PLoS ONE. (2012) 7:e40523. 10.1371/journal.pone.0040523
- Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. (2014) 6:13. 10.12703/P6-13
- Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, et al. . Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest. (2013) 123:4464–78. 10.1172/JCI68189
- Marigo I, Bosio E, Solito S, Mesa C, Fernandez A, Dolcetti L, et al. . Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity. (2010) 32:790–802. 10.1016/j.immuni.2010.05.010
- Strauss L, Sangaletti S, Consonni FM, Szebeni G, Morlacchi S, Totaro MG, et al. . RORC1 regulates tumor-promoting “emergency” granulo-monocytopoiesis. Cancer Cell. (2015) 28:253–69. 10.1016/j.ccell.2015.07.006
- Kuroda E, Noguchi J, Doi T, Uematsu S, Akira S, Yamashita U. IL-3 is an important differentiation factor for the development of prostaglandin E2-producing macrophages between C57BL/6 and BALB/c mice. Eur J Immunol. (2007) 37:2185–95. 10.1002/eji.200737041
- Rath M, Muller I, Kropf P, Closs EI, Munder M. Metabolism via arginase or nitric oxide synthase: two competing arginine pathways in macrophages. Front Immunol. (2014) 5:532. 10.3389/fimmu.2014.00532
- Martinez FO, Helming L, Milde R, Varin A, Melgert BN, Draijer C, et al. . Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood. (2013) 121:e57–69. 10.1182/blood-2012-06-436212
- Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein. J Hematol Oncol. (2017) 10:36. 10.1186/s13045-017-0408-0
- El Chartouni C, Schwarzfischer L, Rehli M. Interleukin-4 induced interferon regulatory factor (Irf) 4 participates in the regulation of alternative macrophage priming. Immunobiology. (2010) 215:821–5. 10.1016/j.imbio.2010.05.031
- Satoh T, Takeuchi O, Vandenbon A, Yasuda K, Tanaka Y, Kumagai Y, et al. . The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol. (2010) 11:936–44. 10.1038/ni.1920
- Lacey DC, Achuthan A, Fleetwood AJ, Dinh H, Roiniotis J, Scholz GM, et al. . Defining GM-CSF- and macrophage-CSF-dependent masHcrophage responses by in vitro models. J Immunol. (2012) 188:5752–65. 10.4049/jimmunol.1103426
- Doherty TM, Kastelein R, Menon S, Andrade S, Coffman RL. Modulation of murine macrophage function by IL-13. J Immunol. (1993) 151:7151–60.
- Doyle AG, Herbein G, Montaner LJ, Minty AJ, Caput D, Ferrara P, et al. . Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-gamma. Eur J Immunol. (1994) 24:1441–5. 10.1002/eji.1830240630
- Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. (2013) 31:317–43. 10.1146/annurev-immunol-032712-095906
- Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP. Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J Biol Chem. (2002) 277:42808–14. 10.1074/jbc.M207840200
- Vergadi E, Ieronymaki E, Lyroni K, Vaporidi K, Tsatsanis C. Akt signaling pathway in macrophage activation and M1/M2 polarization. J Immunol. (2017) 198:1006–14. 10.4049/jimmunol.1601515
- Jinushi M, Nakazaki Y, Dougan M, Carrasco DR, Mihm M, Dranoff G. MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF. J Clin Invest. (2007) 117:1902–13. 10.1172/JCI30966
- Dorhoi A, Du Plessis N. Monocytic myeloid-derived suppressor cells in chronic infections. Front Immunol. (2017) 8:1895. 10.3389/fimmu.2017.01895
- Dilek N, van Rompaey N, Le Moine A, Vanhove B. Myeloid-derived suppressor cells in transplantation. Curr Opin Organ Transplant. (2010) 15:765–8. 10.1097/MOT.0b013e3283401742
- Rodriguez PC, Quiceno DG, Ochoa AC. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood. (2007) 109:1568–73. 10.1182/blood-2006-06-031856
- Bronte V, Serafini P, Mazzoni A, Segal DM, Zanovello P. L-arginine metabolism in myeloid cells controls T-lymphocyte functions. Trends Immunol. (2003) 24:302–6. 10.1016/S1471-4906(03)00132-7
Source: PubMed